EDGE
23.2.2021 17:42:03 CET | Business Wire | Press release
HALCON, a regional leader in the production and supply of precision-guided weapons, today unveiled SkyKnight - the first UAE designed and manufactured counter-rocket, artillery, and mortar (C-RAM) missile system, at the International Defence and Exhibition Conference (IDEX) 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005887/en/
EDGE, the parent company of HALCON, has been developing a short-range air defence system, as has Germany-based Rheinmetall AG, which was actively seeking a missile system to form part of its Skynex air defence system. The companies decided to jointly offer a solution, with HALCON providing SkyKnight, the missile system to the highly regarded Oerlikon Skynex Air Defence System, which sets new standards with its unique open architecture.
HALCON’s SkyKnight was purposely designed to counter the full spectrum of modern threats, providing early warning signals and precise surface-to-air intercept capabilities targeting of rotary-wing aircraft, unmanned aerial vehicles (UAVs) rockets, artillery, mortar, and other fixed-wing aircraft at a range of up to 10Km.
Commenting on this landmark international elevation of a UAE-manufactured missile, H.E. Faisal Al Bannai, EDGE Group CEO and Managing Director said: “SkyKnight is the UAE’s first, but will not be the last air defence missile developed by HALCON. We are pleased to team up with Rheinmetall, a leading player in the defence industry, for us to jointly offer the world’s most advanced and comprehensive C-RAM solution leveraging our SkyKnight missile and Rheinmetall’s Skynex solution. This collaboration is a clear message that EDGE is open to teaming up with various players to offer joint advance solutions.”
The Oerlikon Skynex air defence system comprises the Oerlikon Skynex control node, multi-sensor units (MSU) featuring active electronically scanned multi-mode radars (AMMR), multiple 35mm revolver guns RG Mk3 and HALCON’s SkyKnight C-RAM missiles and missile launchers, each of which has a capacity of 60 missiles. HALCON’s C-RAM missile is capable of tracking and neutralising numerous, multi-directional incoming targets at one time, providing protection for static assets, as well as for mobile and mechanised forces. Transportable and mobile, the system can be deployed fixed on land, sea and moving land platform.
Rheinmetall AG, through its Swiss subsidiary, Rheinmetall Air Defence, has deployed the Skyguard system in numerous countries, which can bring down fast, small targets, and is used as the inner tier of layered air defence of vital points and critical military infrastructure. Countries that have rolled out Skyguard systems will ultimately upgrade to Skynex, placing HALCON, its SkyKnight C-RAM missile system, and the UAE at the forefront of air defence system innovation.
HALCON is part of the Missiles & Weapons cluster within EDGE, an advanced technology group for defence that ranks among the top 25 military suppliers in the world.
About EDGE
EDGE is an advanced technology group established to develop agile, bold and disruptive solutions for defence and beyond. Enabling a secure future, it is dedicated to bringing innovative technologies and services to market with greater speed and efficiency. Consolidating over 25 entities and employing more than 13,000 brilliant minds, it offers expertise across five core clusters: Platforms & Systems, Missiles & Weapons, Cyber Defence, Electronic Warfare & Intelligence and Mission Support. Headquartered in Abu Dhabi, United Arab Emirates, EDGE is a catalyst for change – set to revolutionise the industry and change its fundamentals.
For more information, visit edgegroup.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005887/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
